Refine your search

Search Results within category "Arthritis & Rheumatic Diseases"

Search all categories

Suggestions within category "Arthritis & Rheumatic Diseases"


Study matches: 10

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.


A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus

This study is for patients with SLE (systemic lupus erythematosus) to determine the effectiveness and safety of drug CC-220 on improving SLE and to see how well the body tolerates the medication.
Jamie Carter at jcarter3@pennstatehealth.psu.edu or 717-531-0003
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Systemic Lupus Erythematosus
Exclusion Criteria:
Diagnosis of Fibromyalgia
Active or history of recurrent bacterial, viral or fungal infections
History of latent or active tuberculosis
History of blood clots in the past year
Show full eligibility criteria
NCT03161483
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Investigation of Remission in Rheumatoid Arthritis

This is an experimental observation study of Rheumatoid arthritis that will examine remission in rheumatoid arthritis by (1) collecting biospecimens of rheumatoid arthritis subsets with collection of clinical data and (2) investigation of etiology of immune tolerance in rheumatoid arthritis.
Danielle Feger at dfeger1@pennstatehealth.psu.edu or 717-531-0003
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Rheumatoid Arthritis by a Rheumatologist
Patient of Penn State Hershey Rheumatology
Exclusion Criteria:
No other connective tissue autoimmune disease other than Sjogren's Syndrome
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE)

This study is for patients diagnosed with systemic lupus erythematosus (SLE) who are taking MMF now and have been taking MMF for 1-2 years and your disease is not active. The purpose of this research study is to find out if patients who have been on MMF for 1 to 2 years and whose disease is quiet can safely stop their MMF medication. This could help standardize treatment for lupus patients in the long-run. Doctors know that continuing MMF for long periods of time can have side effects and they know that stopping MMF will put patients at a higher risk for flare; we are trying to find out how big this risk is and if it is better to stop or continue taking MMF.
Jamie Carter at jcarter3@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Lupus
Currently taking Mycophenolate
Taking Hydroxychloroquine
Exclusion Criteria:
Taking prednisone greater than 25mg per day
Show full eligibility criteria
NCT01946880
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE)

This is a study to test whether a widely-used drug, hydroxychloroquine, might slow the progression of lupus like features in individuals who are at high risk for developing systemic lupus erythematosus. This will be measured by the accumulation of clinical and laboratory features of lupus. The study will randomize subjects to the active drug, hydroxychloroquine, or placebo, with an equal chance of receiving either treatment. The study treatment lasts approximately 2 years with visits approximately every 3 months.
Jamie Carter at jcarter3@pennstatehealth.psu.edu or 717-531-4921
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Positive for ANA (antinuclear antibodies)
Age 18 to 45 years, inclusive
Have never taken hydroxychloroquine
Exclusion Criteria:
Previous use of immunosuppressive drugs
Diagnosis of systemic lupus erythematosus
Show full eligibility criteria
NCT03030118
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus

This study is for patients with Systemic Lupus Erythematosus (SLE) to test the effect, safety, and tolerability of the experimental drug JBT-101 in people with SLE to see if JBT-101 stops inflammation and how well JBT-101 is tolerated. The study will evaluate whether JBT-101 will decrease the pain associated with active arthritis or tendonitis in SLE patients.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Be willing to not start or stop any NSAID or disease modifying treatments for SLE during the study
Be wiling to not use any legal or illegal cannabinoids, including FDA-approved cannabinoids during study participation
If female of child-bearing potential must be willing to use highly effective contraception during study participation
Exclusion Criteria:
Treatment with steroids in the past 28 days
Actively listed on organ transplant list or have received an organ transplant other than a corneal transplant
Have active or chronic infections
Have a history of cancer (except cervical treated successfully with curative therapy or basal cell carcinoma)
Have a history of significant heart disease
Show full eligibility criteria
NCT03093402
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2a, Double Blind, Placebo Controlled Study of RSLV-132 In Subjects With Systemic Lupus Erythematosus

RSLV-132 is an investigational drug being developed for the treatment of autoimmune diseases such as Systemic Lupus Erythematosus (SLE, also referenced as lupus) which is affecting your skin.
Jamie Carter at jcarter3@pennstatehealth.psu.edu or 717-531-4921
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Must have diagnosis of SLE according to the ACR criteria
Must have skin disease manifestations
Have elevated autoantibodies on lab resutls
Must be between the ages of 18-70
minimum weight of 45kg
Exclusion Criteria:
Recent use of immunosuppressive drugs
Current active infections
Pregnant or breast feeding
Show full eligibility criteria
NCT02660944
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of Delayed-Release Prednisone (RAYOS®) Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in subjects with Generalized Systemic Lupus Erythematosus

The purpose of this study is to evaluate whether RAYOS®, which is a delayed-release form of prednisone, is safe and effective in managing symptoms of lupus, such as fatigue and morning stiffness and how it affects a person's lupus disease. In addition, this study will compare RAYOS® with a placebo and immediate-release prednisone to see if taking RAYOS® is better than taking a placebo or immediate-release prednisone.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Patients diagnosed with systemic lupus erythematosus or SLE
Must be on a stable dose of prednisone for the past 30 days
Willing to answer study questionnaires daily
Exclusion Criteria:
Patients who have previously taken RAYOS
Diagnosed with fibromyalgia
Have rapidly progressing neurologic or kidney disease
Show full eligibility criteria
NCT03098823
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Observational Study for Pediatric Rheumatic Diseases: The CARRA Registry

The original Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry was first established in 2010 to advance alliance infrastructure,facilitate expanded clinical and translational pediatric research, and transform the culture of pediatric rheumatology toward universal participation in research. Continuation of the CARRA Registry as described in the protocol attached to this IRB submission will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including examining safety questions. The Duke Clinical Research Institute (DCRI) is serving as the CARRA Clinicaland Data Coordinating Center (CDCC) for this protocol.
Jessica Beiler at jbeiler@hmc.psu.edu
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Onset of rheumatic disease prior to age 16 years for Juvenile Idiopathic Arthritis
Onset prior to age 19 years for all other rheumatic diseases
Willing to participate in a registry you will be followed during your treatment and have information about you disease and treatment collected.
Exclusion Criteria:
More than 21 years of age.
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severly Active Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE): Oral medication, Females 18-75 years old with Moderate-to-Severe Active CLE. This is a 24 week study with the option of a 24 week extension period.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Stable dose of antimalarials and topical/oral corticosteroids
No evidence of active or latent TB
Exclusion Criteria:
Have highly active inflammatory/autoimmune/rheumatic disease
Positive test result for HIV
Positive for Hepatitis C / Hepatitis B
Major surgery within 30 days prior to study start
Show full eligibility criteria
NCT03134222
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE

To estimate the proportion of subjects who flare within 40 weeks following withdrawal of ETN in subjects who have achieved ASDAS CRP less than 1.3 (inactive disease).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Back Pain
Symptoms longer than 3 months less than 5 years
On a stable NSAID
ages 18-50
Exclusion Criteria:
Radiographic Sacroilitis
Previous treatment with a TNF-a Biologic inhibitor
Show full eligibility criteria
NCT02509026
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA